Who Owns Kalaris Therapeutics Stock?
NASDAQ: KLRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 12:14 PM ET
Ownership breakdown
- Held by institutions
- 75.84%
- Held by insiders
- 8.81%
- Institutional holders
- 63
- Institutions 75.8%
- Insiders 8.8%
- Public and other 15.3%
Who owns Kalaris Therapeutics stock?
Institutional investors own about 75.8% of Kalaris Therapeutics's shares, spread across 63 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 8.81% of KLRS.
The largest institutional holders are Samsara BioCapital, LLC (54.11%), RTW Investments LP (5.46%) and Alyeska Investment Group, L.p. (2.41%). Together, the top 10 institutions control 69.8% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their KLRS positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of KLRS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Samsara BioCapital, LLC | 12.88M | 54.11% | -0.5% |
| RTW Investments LP | 1.30M | 5.46% | 0.0% |
| Alyeska Investment Group, L.p. | 572.69K | 2.41% | 0.0% |
| Siren, L.L.C. | 435.80K | 1.83% | 0.0% |
| Vanguard Capital Management LLC | 398.71K | 1.67% | +56.1% |
| Ikarian Capital, LLC | 360.00K | 1.51% | 0.0% |
| UBS Group AG | 262.13K | 1.10% | +4138.9% |
| Renaissance Technologies, LLC | 149.35K | 0.63% | +125.8% |
| Marshall Wace LLP | 139.20K | 0.58% | +105.1% |
| Geode Capital Management, LLC | 114.04K | 0.48% | +30.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of KLRS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 255.34K | 1.07% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 137.37K | 0.58% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 58.88K | 0.25% |
| iShares Trust-iShares Micro-Cap ETF | 25.75K | 0.11% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 16.28K | 0.07% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 13.92K | 0.06% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 13.67K | 0.06% |
| GOLDMAN SACHS TRUST-Goldman Sachs Absolute Return Tracker Fund | 8.02K | 0.03% |
| Varbl Insurance Prod. Fd. II-VIP Disciplined Small Cap PORT. | 7.81K | 0.03% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 6.00K | 0.03% |
Frequently asked questions
Who is the largest shareholder of Kalaris Therapeutics?
Samsara BioCapital, LLC is the largest institutional shareholder of KLRS, owning 54.11% of shares outstanding (12.88M shares) as of its latest 13F filing.
What percentage of Kalaris Therapeutics is owned by institutions?
Institutions own about 75.8% of KLRS shares and 83.2% of the public float.
How much of Kalaris Therapeutics do insiders own?
Insiders, such as officers and directors, own about 8.81% of KLRS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.